Infraredx, Inc. describes its TVC Imaging System™ as being capable of the true vessel characterization of coronary artery disease. It tells us the system will be highlighted in 13 presentations during the annual Transcatheter Cardiovascular Therapeutics Meeting (TCT 2013) which starts this Sunday (27th October) in San Francisco.
Background
Infraredx describes itself as a medical device company committed to advancing the diagnosis and management of coronary artery disease.
The TVC Imaging System is a first-in-class intravascular imaging system that enables clinicians to assess both the structure and composition of obstructive plaque in the coronary arteries and to guide interventional treatments for better procedural outcomes. It integrates near-infrared spectroscopy (NIRS) lipid core plaque (LCP) detection technology and enhanced intravascular ultrasound (IVUS) imaging to visualize the presence of plaques, quantify the degree of vessel stenosis (narrowing) and identify lipid core plaques prone to rupturing and causing dangerous blood clots.
The TVC Imaging System™, Infraredx is changing the way coronary artery disease is diagnosed and treated. Infraredx says it is the only intravascular imaging system that enables true vessel characterization through simultaneous structural and compositional imaging data obtained in a single pullback.
The TCT meetings have become the world’s largest educational events to specialize in interventional cardiovascular medicine. The schedule for presentations featuring the TVC Imaging System can be found on its press release, here.
Company comments
“We’re pleased to announce that our TVC Imaging System will be the focus of several presentations led by the world’s premier thought-leaders in interventional cardiology at this year’s TCT meeting,” said Don Southard, president and chief executive officer of Infraredx. “As the pioneer in true vessel characterization, Infraredx provides clinicians with a comprehensive solution to enhance diagnostic accuracy, improve procedural outcomes and potentially define treatment strategies.”
Source: Infraredx, Inc., Business Wire
